ライフサイエンスコーパス: tartrate-resistant acid phosphatase

1 ) were stained with hematoxylin and eosin or tartrate-resistant acid phosphatase.

2 sections stained with hematoxylin-eosin and tartrate-resistant acid phosphatase.

3 orrelated with expression of the target gene tartrate-resistant acid phosphatase.

4 ent decrease in secretion of cathepsin B and tartrate-resistant acid phosphatase.

5 The number of osteoclasts was determined by tartrate-resistant acid phosphatase.

6 ors including NFAT2, TRAF6, cathepsin K, and tartrate-resistant acid phosphatase.

7 lcin, bone-specific alkaline phosphatase, or tartrate-resistant acid phosphatase.

8 -cells, c1 (NFATc1), cathepsin K (Cstk), and tartrate-resistant acid phosphatase 5 (TRAP) with recept

9 unting of the in vivo bone resorption marker tartrate-resistant acid phosphatase 5b (TRACP 5b).

10 serum bone alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRAP-5b), and ca

11 this was accompanied by an increase in serum Tartrate-resistant acid phosphatase 5b (TRAP5b) levels.

12 Even though tartrate-resistant acid phosphatase 5b was expressed, pr

13 rocollagen type-1 N-terminal propeptide, and tartrate-resistant acid phosphatase 5b were associated w

14 elopeptide of type I collagen) and TRACP-5b (tartrate-resistant acid phosphatase 5b).

15 droxyvitamin D, 1,25-dihydroxyvitamin D, and tartrate-resistant acid phosphatase 5b.

16 procollagen type-1 N-terminal propeptide, or tartrate-resistant acid phosphatase 5b; these values cor

17 Serum levels of human OPG-Fc and tartrate-resistant acid phosphatase-5b (TRAP-5b) were me

18 xpress the purple, band 5 isozyme (Acp 5) of tartrate-resistant acid phosphatase, a binuclear metallo

19 ophospholipase A, and tartrate-sensitive and tartrate-resistant acid phosphatase activities and influ

20 d by analyses for calcium release or uptake, tartrate-resistant acid phosphatase activity (marker for

21 eveal a previously unrecognized link between tartrate-resistant acid phosphatase activity and interfe

22 L) groups through histomorphometry and TRAP (tartrate-resistant acid phosphatase activity assay) assa

23 nto osteoclasts was assessed by staining for tartrate-resistant acid phosphatase activity.

24 xacin; V-ATPase, vacuolar H(+)-ATPase; TRAP, tartrate-resistant acid phosphatase; alphaMEM D10, minim

25 factor I concentrations and increased serum tartrate-resistant acid phosphatase and 25-hydroxyvitami

26 ive induction of OCL-specific genes, such as tartrate-resistant acid phosphatase and immunoreceptor O

27 Tartrate-resistant acid phosphatase and osteocalcin were

28 A decrease in immunostaining for tartrate-resistant acid phosphatase and RANKL, an increa

29 e, multinucleated osteoclasts that expressed tartrate-resistant acid phosphatase and were capable of

30 ing matrix metalloproteinase 9, cathepsin K, tartrate-resistant acid phosphatase, and carbonic anhydr

31 ure, downregulation of the HCL markers CD25, tartrate-resistant acid phosphatase, and cyclin D1, smoo

32 assessed were bone resorption, detection of tartrate-resistant acid phosphatase, and determination o

33 OCs, including multinucleation, presence of tartrate-resistant acid phosphatase, and expression of t

34 m the center of the lesion, were stained for tartrate-resistant acid phosphatase, and histomorphometr

35 ls, expression of receptors for AGEs (RAGE), tartrate-resistant acid phosphatase, and proliferating c

36 expression of the receptor for AGEs (RAGE), tartrate-resistant acid phosphatase, and proliferating c

37 line phosphatase, bone alkaline phosphatase, tartrate-resistant acid phosphatase, and urinary cross-l

38 nduce osteoclast formation was determined by tartrate resistant acid phosphatase assay.

39 sed by enzyme-linked immunosorbent assay and tartrate-resistant acid phosphatase assay.

40 teoclast-associated gene expression of TRAP (tartrate-resistant acid phosphatase), cathepsin K, calci

41 gulate calcitonin receptor, but they express tartrate-resistant acid phosphatase, cathepsin K, and be

42 ophathalmia-associated transcription factor, tartrate-resistant acid phosphatase, cathepsin K, and be

43 urface membrane phospho-monoesterase, i.e. a tartrate-resistant acid phosphatase (Cl MAcP) was also f

44 enerated with a transgenic construct using a tartrate-resistant acid phosphatase exon 1C promoter to

45 new bone was being deposited in the socket, tartrate-resistant acid phosphatase-expressing osteoclas

46 could collaborate with MITF to activate the tartrate-resistant acid phosphatase gene promoter depend

47 lammation were assessed by histomorphometry, tartrate-resistant acid phosphatase histoenzymology, and

48 e response was assessed by histomorphometry, tartrate-resistant acid phosphatase histoenzymology, bet

49 Sequencing of ACP5, encoding tartrate-resistant acid phosphatase, identified bialleli

50 eptor type 4, nuclear factor kappa beta, and tartrate-resistant acid phosphatase immunostaining.

51 ollagen type 1 amino-terminal propeptide and tartrate-resistant acid phosphatase in KO mice confirmed

52 iding cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo.

53 vely expresses a unique externally oriented, tartrate-resistant, acid phosphatase on its surface memb

54 Osteoclast morphology was analyzed in tartrate-resistant acid phosphatase or F-actin-stained s

55 crophage marker CD11b, the osteoclast marker tartrate-resistant acid phosphatase, or carbonic anhydra

56 proximately 5% of the mononuclear cells were tartrate-resistant acid phosphatase positive, and these

57 specimens contained MNCs that were intensely tartrate-resistant acid phosphatase positive; approximat

58 TRAP (tartrate-resistant acid phosphatase)-positive osteoclast

59 sections were assessed for the abundance of Tartrate Resistant Acid Phosphatase-positive osteoclasts

60 ssenger RNA and protein, along with elevated tartrate-resistant acid phosphatase-positive (TRAP+) OCs

61 ha tumors associated with significantly more tartrate-resistant acid phosphatase-positive (TRAP+) ost

62 pressed the differentiation and formation of tartrate-resistant acid phosphatase-positive (TRAP+) ost

63 ns, serum interleukin (IL)-1beta levels, and tartrate-resistant acid phosphatase-positive (TRAP+) ost

64 y features of the osteoclast: multinucleated tartrate-resistant acid phosphatase-positive cell format

65 lasts as the number of pits produced by each tartrate-resistant acid phosphatase-positive cell is red

66 Mice with depletion of PDGF-BB in the tartrate-resistant acid phosphatase-positive cell lineag

67 The number of multinucleated tartrate-resistant acid phosphatase-positive cells along

68 wer maturation into osteoclasts with reduced tartrate-resistant acid phosphatase-positive cells and d

69 gt-deleted mice showed a decreased number of tartrate-resistant acid phosphatase-positive cells linin

70 These multinucleated, tartrate-resistant acid phosphatase-positive cells were

71 ion and maintenance of large multinucleated, tartrate-resistant acid phosphatase-positive cells.

72 quantified by histological identification of tartrate-resistant acid phosphatase-positive cells.

73 x metalloproteinase 9, and the generation of tartrate-resistant acid phosphatase-positive multinuclea

74 cent to and distal from pannus invasion, and tartrate-resistant acid phosphatase-positive multinuclea

75 (C453S) significantly enhanced the number of tartrate-resistant acid phosphatase-positive multinuclea

76 GM1 with primary bone marrow cells generated tartrate-resistant acid phosphatase-positive multinuclea

77 RANKL stimulation, have bigger and stronger tartrate-resistant acid phosphatase-positive multinuclea

78 No tartrate-resistant acid phosphatase-positive multinuclea

79 ion were evaluated by counting the number of tartrate-resistant acid phosphatase-positive multinuclea

80 teoclast cell fusion, forming multinucleated tartrate-resistant acid phosphatase-positive osteoclast-

81 egenerative cell lines reduced the number of tartrate-resistant acid phosphatase-positive osteoclast-

82 ells in vitro, as evidenced by a decrease in tartrate-resistant acid phosphatase-positive osteoclasts

83 yelomonocytic precursors into multinucleated tartrate-resistant acid phosphatase-positive osteoclasts

84 kness were increased, and significantly more tartrate-resistant acid phosphatase-positive osteoclasts

85 The number of tartrate-resistant acid phosphatase-positive osteoclasts

86 ysis was characterized by reduced numbers of tartrate-resistant acid phosphatase-positive osteoclasts

87 Catabolic activity was analyzed with tartrate-resistant acid phosphatase-positive osteoclasts

88 We identified tartrate-resistant acid phosphatase-positive osteolytic

89 or induction of bone marrow macrophages into tartrate-resistant acid phosphatase-positive preosteocla

90 -29b, or -29c diminished formation of TRAP (tartrate-resistant acid phosphatase-positive) multinucle

91 eated with aPDT exhibited reduced numbers of tartrate-resistant acid-phosphatase-positive cells and m

92 We used the tartrate-resistant acid phosphatase promoter to target t

93 Tartrate-resistant acid phosphatase reaction and immunoh

94 A parallel series of tartrate resistant acid phosphatase-stained sections wer

95 Osteoclasts were counted in tartrate-resistant acid phosphatase-stained sections.

96 ained slides and osteoclasts were counted on tartrate-resistant acid phosphatase-stained slides.

97 Tartrate resistant acid phosphatase staining of tibia in

98 were evaluated by hematoxylin and eosin and tartrate-resistant acid phosphatase staining (TRAP).

99 into osteoclasts, as evidenced by increased tartrate-resistant acid phosphatase staining and bone re

100 and function were assessed via quantitative tartrate-resistant acid phosphatase staining and degrada

101 Tartrate-resistant acid phosphatase staining demonstrate

102 Mmp-2, and Mmp-14 were expressed widely, and tartrate-resistant acid phosphatase staining notably was

103 ysis, microcomputed tomography analysis, and tartrate-resistant acid phosphatase staining revealed re

104 Tartrate-resistant acid phosphatase staining showed that

105 Tartrate-resistant acid phosphatase staining was used to

106 leated giant cells with varying intensity of tartrate-resistant acid phosphatase staining were regula

107 H&E and tartrate-resistant acid phosphatase staining were used t

108 human preosteoclastic cells was assessed by tartrate-resistant acid phosphatase staining, whereas th

109 hemistry, and osteoclasts were enumerated by tartrate-resistant acid phosphatase staining.

110 ated osteoclastic cells was determined after tartrate-resistant acid phosphatase staining.

111 al fluid (SF) macrophages were determined by tartrate-resistant acid phosphatase staining.

112 PBMC differentiation to OCs was confirmed by tartrate-resistant acid phosphatase staining; bone resor

113 ults of ALP (Alkaline phosphatase) and TRAP (tartrate-resistant acid phosphatase) staining signifies

114 mouse tails, using hematoxylin and eosin and tartrate-resistant acid phosphatase to confirm the prese

115 Meanwhile, CLA significantly reduced femur tartrate resistant acid phosphatase (TRAP) activity, sug

116 Hemin inhibits transcription of the tartrate resistant acid phosphatase (TRAP) gene.

117 en c-src proto-oncogene from the promoter of tartrate resistant acid phosphatase (TRAP), a gene that

118 stal side of the molars until 6 months using tartrate resistant acid phosphatase (TRAP).

119 The enzyme tartrate resistant acid phosphatase (TRAP, two isoforms

120 However, the absence of tartrate-resistant acid phosphatase (TRAP) activity and

121 ic differentiation as evidenced by increased tartrate-resistant acid phosphatase (TRAP) activity and

122 the number of multinuclear cells expressing tartrate-resistant acid phosphatase (TRAP) activity prod

123 The inhibition of osteoclastogenesis and tartrate-resistant acid phosphatase (TRAP) activity was

124 ounterparts they are larger, fail to express tartrate-resistant acid phosphatase (TRAP) activity, and

125 e colocalization of messenger RNA (mRNA) for tartrate-resistant acid phosphatase (TRAP) and cathepsin

126 toplasmic, calcineurin-dependent 1 (NFATc1), tartrate-resistant acid phosphatase (TRAP) and cathepsin

127 one healing/BH), number of cells stained for tartrate-resistant acid phosphatase (TRAP) and immunohis

128 Tartrate-resistant acid phosphatase (TRAP) and microtomo

129 ere performed on media and cell lysates, and tartrate-resistant acid phosphatase (TRAP) and mRNA dete

130 Serial sections were reacted for tartrate-resistant acid phosphatase (TRAP) and nonspecif

131 -dihydroxycholecalciferol and coincided with tartrate-resistant acid phosphatase (TRAP) expression, a

132 d alkaline phosphatase (AP) for osteoblasts; tartrate-resistant acid phosphatase (TRAP) for osteoclas

133 ast differentiation, plays a pivotal role in tartrate-resistant acid phosphatase (TRAP) gene expressi

134 a novel CD gene regulated by the osteoclast tartrate-resistant acid phosphatase (TRAP) gene promoter

135 e sialoprotein (BSP), osteocalcin (OCN), and tartrate-resistant acid phosphatase (TRAP) immunohistoch

136 IL-4 down-regulates expression of tartrate-resistant acid phosphatase (TRAP) in mature ost

137 ecessary for activation of target genes like tartrate-resistant acid phosphatase (TRAP) in osteoclast

138 Tartrate-resistant acid phosphatase (TRAP) is an iron-co

139 The tartrate-resistant acid phosphatase (TRAP) is present in

140 d hematoxylin and eosin and subjected to the tartrate-resistant acid phosphatase (TRAP) method.

141 These MNCs were also positive for tartrate-resistant acid phosphatase (TRAP) mRNA and TRAP

142 Tartrate-resistant acid phosphatase (TRAP) plays an impo

143 le extracts of PRF membranes as indicated by tartrate-resistant acid phosphatase (TRAP) staining and

144 Tartrate-resistant acid phosphatase (TRAP) staining show

145 was analyzed by immunohistochemistry, using tartrate-resistant acid phosphatase (TRAP) staining to i

146 Tartrate-resistant acid phosphatase (TRAP) staining, res

147 Bone lesion was evaluated by Tartrate-resistant acid phosphatase (TRAP) staining.

148 Osteoclastic activity was measured by tartrate-resistant acid phosphatase (TRAP) staining.

149 uCT and osteoclast number was determined by tartrate-resistant acid phosphatase (TRAP) staining.

150 nalysis and immunohistochemical detection of tartrate-resistant acid phosphatase (TRAP) were also per

151 B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP) were assessed

152 Histological sections stained for tartrate-resistant acid phosphatase (TRAP) were quantifi

153 a strongly reduced formation of multinuclear tartrate-resistant acid phosphatase (TRAP)(+) osteoclast

154 appaB ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphatase (TRAP), and activate

155 eptor activator of NK-kappaB ligand (RANKL), tartrate-resistant acid phosphatase (TRAP), and osteocla

156 ocollagen I carboxy-terminal propeptide, and tartrate-resistant acid phosphatase (TRAP), and urinary

157 on of matrix metallopeptidase 13 (MMP13) and tartrate-resistant acid phosphatase (TRAP), leading to a

158 Cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP), Oregon Green

159 BL, TBA, the positive cells for tartrate-resistant acid phosphatase (TRAP), receptor act

160 inflammatory cells, immunostained cells for tartrate-resistant acid phosphatase (TRAP), the receptor

161 significant elevation of the active form of tartrate-resistant acid phosphatase (TRAP)-5b.

162 sence of IL-4, we detected the appearance of tartrate-resistant acid phosphatase (TRAP)-negative mult

163 st/periodontal ligament cells displayed more tartrate-resistant acid phosphatase (TRAP)-positive cell

164 counted as bone-associated multi-nucleated, tartrate-resistant acid phosphatase (TRAP)-positive cell

165 nificantly lower level of bone loss and less tartrate-resistant acid phosphatase (TRAP)-positive cell

166 igature-induced bone loss in mice with fewer tartrate-resistant acid phosphatase (TRAP)-positive cell

167 confirmed the decreased bone mass, increased tartrate-resistant acid phosphatase (TRAP)-positive cell

168 NF-kappaB ligand formation of multinucleated tartrate-resistant acid phosphatase (TRAP)-positive cell

169 Tartrate-resistant acid phosphatase (TRAP)-positive oste

170 matoxylin and eosin, immunohistochemical, or tartrate-resistant acid phosphatase (TRAP)-stained secti

171 ltinucleated cells that stained positive for tartrate-resistant acid phosphatase (TRAP).

172 B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP).

173 s showed increased numbers of multinucleated tartrate-resistant acid phosphatase (TRAP)/cathepsin K(+

174 protein 2/4 [BMP2/4], osteocalcin [OCN], and tartrate-resistant acid phosphatase [TRAP]) analyses wer

175 rome), histomorphometry and immunohistology (Tartrate-Resistant Acid Phosphatase-TRAP, Osteocalcin an

176 otegerin expression, and a decrease in serum tartrate-resistant acid phosphatase (TRAP5b) concentrati

177 1, NF-kappaB ligand, cathepsin K, and serum tartrate-resistant acid phosphatase type 5b, but ankle l

178 Tartrate-resistant acid phosphatase (type V) (TRAP) was

179 a large number of mononuclear cells bearing tartrate resistant acid phosphatase were observed on cel

180 of nuclear factor-kappaB ligand (RANKL) and tartrate resistant acid phosphatase were significantly d

181 received Scl-AbI, although levels of type 5b tartrate-resistant acid phosphatase were significantly l